# Albany College of Pharmacy and Health Sciences

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/albany-college-of-pharmacy-and-health-sciences/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 46.7 |
| Citations | 190,633 |
| City | Albany |
| Country | US |
| Description | Albany College of Pharmacy and Health Sciences is a research organisation in Albany, US. OpenAlex records 3,411 works and 190,633 citations for it. 843 researchers list it as their most recent affiliation. |
| Homepage | https://www.acphs.edu |
| OpenAlex ID | https://openalex.org/I365282 |
| Researchers | 843 |
| ROR ID | https://ror.org/014hfaw95 |
| Type | education |
| Wikidata ID | https://www.wikidata.org/wiki/Q2830804 |
| Works | 3,411 |

## University papers

Showing 12 of 31.

- [Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial](https://scholariq.org/papers/efficacy-and-safety-of-cefiderocol-or-best-available-therapy-for-the-treatment/)
- [Peritoneal Dialysis-Related Infections Recommendations: 2005 Update](https://scholariq.org/papers/peritoneal-dialysis-related-infections-recommendations-2005-update/)
- [Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial](https://scholariq.org/papers/dulaglutide-versus-insulin-glargine-in-patients-with-type-2-diabetes-and/)
- [Drug dosing consideration in patients with acute and chronic kidney disease—a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)](https://scholariq.org/papers/drug-dosing-consideration-in-patients-with-acute-and-chronic-kidney-disease-a/)
- [Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial](https://scholariq.org/papers/oral-semaglutide-versus-empagliflozin-in-patients-with-type-2-diabetes/)
- [Adult Peritoneal Dialysis-Related Peritonitis Treatment Recommendations: 2000 Update](https://scholariq.org/papers/adult-peritoneal-dialysis-related-peritonitis-treatment-recommendations-2000/)
- [Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial](https://scholariq.org/papers/semaglutide-once-weekly-as-add-on-to-sglt-2-inhibitor-therapy-in-type-2-diabetes/)
- [Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial](https://scholariq.org/papers/efficacy-and-safety-of-oral-semaglutide-in-patients-with-type-2-diabetes-and/)
- [Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial](https://scholariq.org/papers/efficacy-and-safety-of-dapagliflozin-in-patients-with-inadequately-controlled/)
- [Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease: An Overview](https://scholariq.org/papers/clinical-practice-guidelines-for-bone-metabolism-and-disease-in-chronic-kidney/)
- [Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study](https://scholariq.org/papers/efficacy-and-safety-of-dapagliflozin-in-patients-with-inadequately-controlled-3/)
- [Chromium Picolinate Toxicity](https://scholariq.org/papers/chromium-picolinate-toxicity/)

## University researchers

- [George R. Bailie](https://scholariq.org/researchers/george-r-bailie/)
- [Robert S. Busch](https://scholariq.org/researchers/robert-s-busch/)
- [Darren W. Grabe](https://scholariq.org/researchers/darren-w-grabe/)

## University top topics

Showing 8 of 25.

- [Antibiotics Pharmacokinetics and Efficacy](https://scholariq.org/topics/antibiotics-pharmacokinetics-and-efficacy/)
- [Urinary Bladder and Prostate Research](https://scholariq.org/topics/urinary-bladder-and-prostate-research/)
- [Antimicrobial Resistance in Staphylococcus](https://scholariq.org/topics/antimicrobial-resistance-in-staphylococcus/)
- [Pharmaceutical Practices and Patient Outcomes](https://scholariq.org/topics/pharmaceutical-practices-and-patient-outcomes/)
- [Antibiotic Resistance in Bacteria](https://scholariq.org/topics/antibiotic-resistance-in-bacteria/)
- [Antibiotic Use and Resistance](https://scholariq.org/topics/antibiotic-use-and-resistance/)
- [Urinary Tract Infections Management](https://scholariq.org/topics/urinary-tract-infections-management/)
- [Venous Thromboembolism Diagnosis and Management](https://scholariq.org/topics/venous-thromboembolism-diagnosis-and-management/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.